Pfizer Inc (PFE) 29.40 $PFE
Most active New York Stock Exchange-traded stocks
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Wed Sep 03, 12:34PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Wed Sep 03, 9:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
ViiV Healthcare receives EU marketing authorisation for Triumeq(R) (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
PR Newswire Europe - Wed Sep 03, 9:06AM CDT
ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq((R)) (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older and weighing at least 40kg. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.(1) Patients who carry this genetic marker are at high risk of experiencing a hypersensitivity reaction to abacavir.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Business Wire - Wed Sep 03, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
BIND Therapeutics Appoints Two New Board Members
Business Wire - Wed Sep 03, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND's management team in the achievement of its business and development goals.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
AstraZeneca Reports Data on Brilinta from ATLANTIC Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:40PM CDT
AstraZeneca (AZN) announced data from the phase IV ATLANTIC study on Brilinta.
Is It Time to Buy Johnson & Johnson's Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:36PM CDT
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks. Healthcare conglomerate Johnson & Johnson would like to put to rest those assumptions based on its...
Is It Time to Buy Pfizer Inc.'s Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:32PM CDT
Since the recession ended, shareholders in Pfizer , the world's largest pharmaceutical company by revenue, have seen their shares more than double. A combination of high-branded drug margins coupled with the expectation that the Affordable Care...
Pfizer (PFE) Approaches New Downside Target of $29.19
Comtex SmarTrend(R) - Tue Sep 02, 8:59AM CDT
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $29.39 today and have reached the first support level of $29.29. Should the shares continue to fall, the support pivots of $29.19 and $28.99 will be of interest.
Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014
M2 - Mon Sep 01, 6:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmprtw/analyzing_the) has announced the addition of the "Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014" report to their offering. This research analyzes the global API industry in its research report Analyzing the Global Market for Active Pharmaceutical Ingredients. The report begins with an introduction to active pharmaceutical ingredients (APIs). An analysis of the global market for APIs includes an industry overview, industry revenues, industry segmentation by the biotech API market and the Synthetic API market and a profile of the High Potency Active Pharmaceutical Ingredient (HPAPAI) Market. We also analyze some of the major impacts on the global API market such as the ongoing and upcoming patent expires of blockbuster drugs and the impact of the economic recession on the market. The global market for active pharmaceutical ingredients has been growing steadily in recent years. However, the recent economic recession slowed down the growth of the industry as investments made by the major players went down significantly. Furthermore with a large number of blockbuster drugs going off patent by the end of 2014, there is expected to be a major impact on the global API industry. Revenues of the API markets are likely to be affected as generic drugs take up the market. The United States remains one of the biggest players in the market, followed closely by China and India. Synthetic pharmaceuticals also continue to dominate the API industry as biotech APIs move up slowly. Major companies such as Teva, Dr Reddy's and Boehringer Ingelheim continue to invest heavily in the API industry and remain the leading players in the global active pharmaceutical ingredient market. Key Topics Covered: 1. Executive Summary 2. Introduction to Active Pharmaceutical Ingredients 3. Global Market for Active Pharmaceutical Ingredients (APIs) 4. Impacts on the Global API Market 5. Market for Active Pharmaceutical Ingredients (APIs) in Asia Pacific 6. Market for Active Pharmaceutical Ingredients (APIs) in Europe 7. Market for Active Pharmaceutical Ingredients (APIs) in North America 8. Major Industry Players - Actavis Plc - Albemarle Corporation - Ampac Fine Chemicals LLC - Aptuit, Inc - Aurobindo Pharma - BASF SE - Biocon Ltd - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cambrex Corporation - Cipla Ltd - Covidien Plc - Daiichi Fine Chemical Co., Ltd. - Dishman Pharmaceuticals & Chemicals Ltd. - Dr. Reddy's Laboratories Limited - Fabbrica Italiana Sintetici - Hospira Inc - Koninklijke DSM N.V. - Lonza Group AG - Lupin Limited - Matrix Laboratories Limited/Mylan Inc - Novartis AG - Novasep Holding - Pfizer Inc - Ranbaxy Laboratories - Sandoz International GmbH - Sigma-Aldrich Corporation - Sun Pharmaceutical Industries Limited - Teva Pharmaceutical Industries Limited - WuXi AppTec, Inc For more information visit http://www.researchandmarkets.com/research/bm...lyzing_the
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
Business Wire - Sat Aug 30, 4:15AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE FE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo. This effect was independent of other variables including renal function, the only other significant predictor of hospitalization in the AMPLIFY-EXT population. These data were presented during an oral session today in Barcelona, Spain, at the ESC Congress 2014.
Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:10PM CDT
Pfizer Inc. (PFE) announced that its vaccine candidate for clostridium difficile infection has been granted fast track designation by the FDA.
BioMed Realty Inks Lease Agreement with GlycoMimetics in MD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:20PM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with GlycoMimetics, Inc. (GLYC) for leasing a property at the Center for Life Science | Shady Grove in Rockville, MD.
Most active New York Stock Exchange-traded stocks
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Wed Sep 03, 12:34PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Wed Sep 03, 9:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
ViiV Healthcare receives EU marketing authorisation for Triumeq(R) (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
PR Newswire Europe - Wed Sep 03, 9:06AM CDT
ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq((R)) (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older and weighing at least 40kg. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.(1) Patients who carry this genetic marker are at high risk of experiencing a hypersensitivity reaction to abacavir.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Business Wire - Wed Sep 03, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
BIND Therapeutics Appoints Two New Board Members
Business Wire - Wed Sep 03, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND's management team in the achievement of its business and development goals.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
AstraZeneca Reports Data on Brilinta from ATLANTIC Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:40PM CDT
AstraZeneca (AZN) announced data from the phase IV ATLANTIC study on Brilinta.
Is It Time to Buy Johnson & Johnson's Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:36PM CDT
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks. Healthcare conglomerate Johnson & Johnson would like to put to rest those assumptions based on its...
Is It Time to Buy Pfizer Inc.'s Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:32PM CDT
Since the recession ended, shareholders in Pfizer , the world's largest pharmaceutical company by revenue, have seen their shares more than double. A combination of high-branded drug margins coupled with the expectation that the Affordable Care...
Pfizer (PFE) Approaches New Downside Target of $29.19
Comtex SmarTrend(R) - Tue Sep 02, 8:59AM CDT
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $29.39 today and have reached the first support level of $29.29. Should the shares continue to fall, the support pivots of $29.19 and $28.99 will be of interest. Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014
M2 - Mon Sep 01, 6:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmprtw/analyzing_the) has announced the addition of the "Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014" report to their offering. This research analyzes the global API industry in its research report Analyzing the Global Market for Active Pharmaceutical Ingredients. The report begins with an introduction to active pharmaceutical ingredients (APIs). An analysis of the global market for APIs includes an industry overview, industry revenues, industry segmentation by the biotech API market and the Synthetic API market and a profile of the High Potency Active Pharmaceutical Ingredient (HPAPAI) Market. We also analyze some of the major impacts on the global API market such as the ongoing and upcoming patent expires of blockbuster drugs and the impact of the economic recession on the market. The global market for active pharmaceutical ingredients has been growing steadily in recent years. However, the recent economic recession slowed down the growth of the industry as investments made by the major players went down significantly. Furthermore with a large number of blockbuster drugs going off patent by the end of 2014, there is expected to be a major impact on the global API industry. Revenues of the API markets are likely to be affected as generic drugs take up the market. The United States remains one of the biggest players in the market, followed closely by China and India. Synthetic pharmaceuticals also continue to dominate the API industry as biotech APIs move up slowly. Major companies such as Teva, Dr Reddy's and Boehringer Ingelheim continue to invest heavily in the API industry and remain the leading players in the global active pharmaceutical ingredient market. Key Topics Covered: 1. Executive Summary 2. Introduction to Active Pharmaceutical Ingredients 3. Global Market for Active Pharmaceutical Ingredients (APIs) 4. Impacts on the Global API Market 5. Market for Active Pharmaceutical Ingredients (APIs) in Asia Pacific 6. Market for Active Pharmaceutical Ingredients (APIs) in Europe 7. Market for Active Pharmaceutical Ingredients (APIs) in North America 8. Major Industry Players - Actavis Plc - Albemarle Corporation - Ampac Fine Chemicals LLC - Aptuit, Inc - Aurobindo Pharma - BASF SE - Biocon Ltd - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cambrex Corporation - Cipla Ltd - Covidien Plc - Daiichi Fine Chemical Co., Ltd. - Dishman Pharmaceuticals & Chemicals Ltd. - Dr. Reddy's Laboratories Limited - Fabbrica Italiana Sintetici - Hospira Inc - Koninklijke DSM N.V. - Lonza Group AG - Lupin Limited - Matrix Laboratories Limited/Mylan Inc - Novartis AG - Novasep Holding - Pfizer Inc - Ranbaxy Laboratories - Sandoz International GmbH - Sigma-Aldrich Corporation - Sun Pharmaceutical Industries Limited - Teva Pharmaceutical Industries Limited - WuXi AppTec, Inc For more information visit http://www.researchandmarkets.com/research/bm...lyzing_the
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
Business Wire - Sat Aug 30, 4:15AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE
FE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo. This effect was independent of other variables including renal function, the only other significant predictor of hospitalization in the AMPLIFY-EXT population. These data were presented during an oral session today in Barcelona, Spain, at the ESC Congress 2014. Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:10PM CDT
Pfizer Inc. (PFE) announced that its vaccine candidate for clostridium difficile infection has been granted fast track designation by the FDA.
BioMed Realty Inks Lease Agreement with GlycoMimetics in MD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:20PM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with GlycoMimetics, Inc. (GLYC) for leasing a property at the Center for Life Science | Shady Grove in Rockville, MD.
